RxDoctor Payments Data

Erica Uppstrom, MD

Cardiovascular Disease · Saint Louis, MONPI 1366441339

Payments from drug & device makers

$1,087in general payments, 2019–2025

Across 44 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$404
  • Novartis$148
  • Abbott$107
  • Boehringer Ingelheim$89
  • E.r. Squibb & Sons, L.L.C.$87
  • Johnson & Johnson$70
  • plus $181 from 6 others

What the payments were for

  • Travel & lodging$14914%
  • Food & beverage$92485%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,087 in reported general payments places this provider in the 35th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$27,621
Medicare patients
198
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban250$234,756
XareltoRivaroxaban169$175,414
EntrestoSacubitril/Valsartan127$107,249
JardianceEmpagliflozin82$58,473
FarxigaDapagliflozin Propanediol34$32,550
Repatha SureclickEvolocumab50$32,419
Praluent PenAlirocumab18$10,852
VascepaIcosapent Ethyl13$5,147
Metoprolol Succinate345$4,722
BrilintaTicagrelor11$4,487
Atorvastatin Calcium359$3,406
Rosuvastatin Calcium199$2,094
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$1,930
Flecainide Acetate30$1,868
Ezetimibe74$1,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$234,756250 claims
Johnson & JohnsonXarelto$70$175,414169 claims
NovartisEntresto$148$107,249127 claims
Boehringer IngelheimJardiance$89$58,47382 claims
AstraZenecaFarxiga, Brilinta$30$37,03745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →